Resolution of vanishing bile duct syndrome in a patient associated with refractory hodgkin lymphoma following Anti-PD-1 therapy: a case report and literature review.

Yi-Ching Lin, Wan-Chen Hsieh, Yu-Hsuan Tuan, Hsu-Hua Tseng, Jia-Huei Tsai, Tung-Hung Su, Tai-Chung Huang

Abstract readCase ReportsReview

In one paragraph

Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-Ching Lin *Department of Internal Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Wan-Chen Hsieh *Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Yu-Hsuan TuanDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Hsu-Hua TsengDivision of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Jia-Huei TsaiDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.

Tung-Hung SuDivision of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Tai-Chung HuangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. tch01@ntu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vanishing bile duct syndrome (VBDS) is a rare, and often fatal complication of Hodgkin lymphoma (HL), characterized by progressive intrahepatic bile duct loss and severe cholestasis. Management remains ill-defined, particularly in patients with refractory HL and significant hepatic dysfunction. We present a case of a young woman with biopsy-proven VBDS who experienced disease progression and worsening cholestasis despite second-line chemotherapy, corticosteroids, and brentuximab vedotin. Salvage therapy with pembrolizumab was initiated, resulting in a complete metabolic remission of HL and normalization of liver function. Notably, the patient did not experience immune-related hepatic adverse events. To our knowledge, this is the first report of HL-related VBDS successfully treated with programmed death-1 blockade. This case suggests that immune checkpoint inhibitors may be a viable therapeutic option for patients with HL-related VBDS, even in the setting of severe hepatic dysfunction.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHodgkin DiseaseImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorFemaleHumansSalvage TherapyYoung AdultAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorAnti–PD-1CholestasisHodgkin lymphomaPembrolizumabVanishing bile duct syndrome

Identifiers

PMID41746393

DOI10.1007/s00277-026-06745-3

PMCPMC12945991

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.